Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 15 Parkinson's papers of 7,703 | 0.64 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2973
Sealed predictions
- G6PD in dopamine neurons, braak-0.05 (p 0.893) → -0.29 (p 0.449)receipt 2980
Swarm cases
receipt 2980: G6PD in dopamine neurons, braak
- power
- full sample -0.19 (p 0.460, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.17 (p 0.493, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.22 (p 0.384, n 18). could be the mix.
- skeptic
- leave-one-out range -0.32 to -0.08, sign flips 0; without severely affected donors -0.19 (p 0.460, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.78 (p 1.2e-4, n 18) vs -0.19 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for G6PD in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up G6PD · oligodendrocytes · braak: substantia nigra, an independent cohort: not measured
Receipts
loading the receipts